<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Literature, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27819257</article-id><article-id pub-id-type="pmc">5110226</article-id><article-id pub-id-type="doi">10.12659/MSM.897596</article-id><article-id pub-id-type="publisher-id">897596</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Preemptive Antifungal Therapy for Febrile Neutropenic Hematological Malignancy Patients in China</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="af1-medscimonit-22-4226">1</xref><xref ref-type="author-notes" rid="fn3-medscimonit-22-4226">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-22-4226">D</xref></contrib><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Jinhai</given-names></name><xref ref-type="aff" rid="af2-medscimonit-22-4226">2</xref><xref ref-type="author-notes" rid="fn1-medscimonit-22-4226">A</xref><xref ref-type="author-notes" rid="fn2-medscimonit-22-4226">B</xref><xref ref-type="corresp" rid="c1-medscimonit-22-4226"/></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Xiaonan</given-names></name><xref ref-type="aff" rid="af2-medscimonit-22-4226">2</xref><xref ref-type="author-notes" rid="fn5-medscimonit-22-4226">E</xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Xiaoling</given-names></name><xref ref-type="aff" rid="af2-medscimonit-22-4226">2</xref><xref ref-type="author-notes" rid="fn6-medscimonit-22-4226">F</xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Shengxin</given-names></name><xref ref-type="aff" rid="af2-medscimonit-22-4226">2</xref><xref ref-type="author-notes" rid="fn6-medscimonit-22-4226">F</xref></contrib></contrib-group><aff id="af1-medscimonit-22-4226"><label>1</label>Department of Hematology, Pingan Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China</aff><aff id="af2-medscimonit-22-4226"><label>2</label>Department of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China</aff><author-notes><corresp id="c1-medscimonit-22-4226">Corresponding Author: Jinhai Ren, e-mail: <email>jinhairen2015@sina.com</email></corresp><fn id="fn1-medscimonit-22-4226"><label>A</label><p>Study Design</p></fn><fn id="fn2-medscimonit-22-4226"><label>B</label><p>Data Collection</p></fn><fn id="fn3-medscimonit-22-4226"><label>C</label><p>Statistical Analysis</p></fn><fn id="fn4-medscimonit-22-4226"><label>D</label><p>Data Interpretation</p></fn><fn id="fn5-medscimonit-22-4226"><label>E</label><p>Manuscript Preparation</p></fn><fn id="fn6-medscimonit-22-4226"><label>F</label><p>Literature Search</p></fn><fn id="fn7-medscimonit-22-4226"><label>G</label><p>Funds Collection</p></fn></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>07</day><month>11</month><year>2016</year></pub-date><volume>22</volume><fpage>4226</fpage><lpage>4232</lpage><history><date date-type="received"><day>15</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>03</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Med Sci Monit, 2016</copyright-statement><copyright-year>2016</copyright-year><license><license-p>This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)</license-p></license></permissions><abstract><sec><title>Background</title><p>The aim of this study was to evaluate the efficiency, adverse effects, and pharmacoeconomic impact of empirical and preemptive antifungal therapy for febrile neutropenic hematological malignancy patients in China.</p></sec><sec><title>Material/Methods</title><p>Patients with febrile neutropenia during hematological malignancy were randomly divided into an empirical group and a preemptive group. The preemptive antifungal treatment was initiated if patient status was confirmed by clinical manifestation, imaging diagnosis, 1-3-&#x003b2;-D glucan(G) testing, and galactomannan (GM) test. The treatment was ended 2 weeks later if the patient was recovered from neutropenia. Voriconazole was used as the first-line medicine. All patients received intravenous administration of voriconazole every 12 h, with an initiating dose of 400 mg, then the dose was reduced to 200 mg.</p></sec><sec><title>Results</title><p>The overall survival rate was 97.1% and 94.6% in the empirical group and preemptive group, respectively, with no significant difference observed (&#x003c7;<sup>2</sup>=1.051, P=0.305). However, the occurrence rate of invasive fungal disease (IFD) in the preemptive group was 9.2% <italic>vs.</italic> 2.2% in the empirical group. Moreover, the mortality rate due to IFD was 0.7% and 2.3% for the empirical group and preemptive group, respectively. The average duration and cost of preemptive antifungal therapy were 13.8&#x000b1;4.7 days and 8379.00&#x000b1;2253.00 RMB, respectively, which were lower than for empirical therapy. However, no significant differences were observed for incidence of adverse effects and hospital stay between the 2 groups.</p></sec><sec><title>Conclusions</title><p>Preemptive antifungal therapy for patients with febrile neutropenic hematological malignancy demonstrated a similar survival rate as with empirical therapy but is economically favorable in a Chinese population.</p></sec></abstract><kwd-group><title>MeSH Keywords</title><kwd>Hematologic Agents</kwd><kwd>Hematologic Diseases</kwd><kwd>Hematologic Neoplasms</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Patients with a hematological malignancy are generally considered as being susceptible to fungal infections, which leads to development of invasive fungal disease (IFD) caused by filamentous fungi [<xref rid="b1-medscimonit-22-4226" ref-type="bibr">1</xref>,<xref rid="b2-medscimonit-22-4226" ref-type="bibr">2</xref>]. Many predisposing or risk factors has been described for the development of IFD, such as intensity and duration of neutropenia, diagnosis of acute leukemia, and severe impairment of lymphocytic activity [<xref rid="b3-medscimonit-22-4226" ref-type="bibr">3</xref>,<xref rid="b4-medscimonit-22-4226" ref-type="bibr">4</xref>]. Currently, empirical antifungal therapy is the classical and standard of the care method for IFD in hematological patients. Generally, the use of antifungal drugs is initiated once clinical evidence of fungal infection is observed [<xref rid="b3-medscimonit-22-4226" ref-type="bibr">3</xref>,<xref rid="b5-medscimonit-22-4226" ref-type="bibr">5</xref>]. Empirical antifungal therapy is frequently recommended for patients with high or medium risk of IFD, such as those with fever for more than 3 days after broad-spectrum antimicrobial therapy [<xref rid="b3-medscimonit-22-4226" ref-type="bibr">3</xref>,<xref rid="b6-medscimonit-22-4226" ref-type="bibr">6</xref>,<xref rid="b7-medscimonit-22-4226" ref-type="bibr">7</xref>]. However, empirical antifungal therapy has a low specificity and certain limitations, such as over-treatment of the patients, drug resistance induction, and higher medical expenses [<xref rid="b3-medscimonit-22-4226" ref-type="bibr">3</xref>,<xref rid="b8-medscimonit-22-4226" ref-type="bibr">8</xref>].</p><p>The concept of preemptive antifungal therapy was recently introduced for IFD therapy in hematological malignancy patients [<xref rid="b9-medscimonit-22-4226" ref-type="bibr">9</xref>]. Briefly, preemptive antifungal therapy is a diagnosis-based therapy that uses antifungals based on the diagnosis of probable fungal infection by results from microbiological tests (e.g., GM testing) or chest computed tomography (CT) [<xref rid="b9-medscimonit-22-4226" ref-type="bibr">9</xref>]. Preemptive antifungal therapy is intended to provide antifungal therapy to early-stage patients to achieve anticipated effects and reduce the overuse of antifungal agents [<xref rid="b9-medscimonit-22-4226" ref-type="bibr">9</xref>,<xref rid="b10-medscimonit-22-4226" ref-type="bibr">10</xref>]. A controlled trial systematically comparing empirical <italic>vs.</italic> preemptive antifungal therapy for high-risk, febrile, neutropenic patients concluded that although preemptive treatment increased the incidence of invasive fungal disease, it did not increase the overall mortality in patients and it reduced the expenses related to antifungal drugs used [<xref rid="b11-medscimonit-22-4226" ref-type="bibr">11</xref>]. However, because this strategy depends on galactomannan testing (GM test) and chest CT, preemptive antifungal therapy has certain disadvantages, such as the delayed initiation of antifungal treatment [<xref rid="b9-medscimonit-22-4226" ref-type="bibr">9</xref>], and the low sensitivity of galactomannan testing for some <italic>Aspergillus fumigatus-</italic>infected patients [<xref rid="b12-medscimonit-22-4226" ref-type="bibr">12</xref>]. In addition, the image markers from chest CT (halo sign or reverse halo sign) are not specific and may be observed in many infectious and non-infectious diseases rather than fungal infection [<xref rid="b13-medscimonit-22-4226" ref-type="bibr">13</xref>]. Therefore, some researchers still view empirical antifungal therapy as a more validated treatment of IFD in patients with hematological malignancy [<xref rid="b3-medscimonit-22-4226" ref-type="bibr">3</xref>].</p><p>Recently, the CDC of China issued a revised guideline of the <italic>Diagnosis Criteria and Treatment Regulation of Hematological Malignancy Patients with Invasive Fungal Disease</italic> (the Forth Revised Edition). In this guideline, application of preemptive antifungal therapy is recommended. We designed this study to evaluate the benefits of preemptive antifungal therapy for Chinese patients.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec><title>Ethics statement</title><p>Institutional Ethics Board approval was obtained from the Medical Ethics Committee of the Second Hospital of Hebei Medical University. All participating patients were formally informed of the purpose of this study and written informed consent was obtained from all participants.</p></sec><sec sec-type="subjects"><title>Patients and groups</title><p>We enrolled 268 patients with hematological malignancy admitted to the Department of Hematology in the Second Hospital of Hebei Medical University from October 2013 to December 2014. All patients were subjected to cytomorphology, histological chemistry and biopsy of bone marrow, subtyping by flow cytometry, detection of fusion gene, and chromosome examination to confirm the occurrence of hematological malignancy. The IFD diagnosis criteria and standard of therapeutic effect were referenced to the <italic>Diagnosis Criteria and Treatment Regulation of Hematological Malignancy Patients with Invasive Fungal Disease</italic> (Forth Revised Edition). All patients were randomly assigned to either the empirical antifungal therapy group (n=138) or the preemptive antifungal therapy group (n=130).</p></sec><sec><title>Inclusion and exclusion criteria</title><p>All patients included in this study met the following criteria: older than 18 years, had hematological malignancy, had a plan of chemotherapy treatment, and had severe neutropenia (less than 0.5 &#x000d7;10<sup>9</sup> neutrophils/L for a minimum duration of 10 days). Patients with any of the following situations were excluded: had received hematopoietic stem cell transplantation, had experience or symptoms of IFD, demonstrated low tolerance to triazoles, HIV-positive, and Karnofsky Performance Status score less than 30 according to the accepted scale system [<xref rid="b14-medscimonit-22-4226" ref-type="bibr">14</xref>]. Moreover, patients were excluded if they had no neutropenia or fever, were treated with antifungal therapy within 4 days of developing a fever, started antifungal therapy without proof of IFD at 4&#x02013;14 days, or had no antifungal treatment but had proof of IFD at 4&#x02013;14 days.</p></sec><sec><title>Medical intervention</title><p>The medical intervention was conducted as previously described [<xref rid="b11-medscimonit-22-4226" ref-type="bibr">11</xref>]. Briefly, 2 blood cultures, 1 urine culture, and related microbiological analysis were conducted for all patients. Patients received broad-spectrum &#x003b2;-lactam antibiotic with or without combination of aminoglycosides according to clinical manifestation. Glycopeptides antibiotics were administrated immediately if the following symptoms occurred: infectious shock, stage IV mucositis according to WHO diagnostic criteria, colonization of infection caused by methicillin-resistant <italic>Staphylococcus aureus</italic> or <italic>Streptococcus pneumoniae,</italic> or catheter-related infections. Glycopeptide antibiotics were added if the fever persisted for 48 h after administration of broad-spectrum &#x003b2;-lactam antibiotic.</p><p>For the empirical treatment group, antifungal therapy was started within 4 days of start of persistent fever and antibacterial treatment. If there was recurrent fever between day 4 and day 14, antifungal therapy was initiated on the day of the recurrence. For the preemptive treatment group, antifungal therapy was initiated immediately if any of the flowing situations occurred: clinical or imaging examination suggested pneumonia, acute sinusitis, stage III mucositis, or most importantly, infectious shock, IFD-related skin damage, central nerve system symptoms due to unknown reason, periorbital inflammation, abscess of liver or spleen, severely diarrhea, colonization by aspergilloma, or (1,3)-&#x003b2;-D-glucan test (G test)-positive and galactomannan test (GM test)-positive. The antifungal therapy was continued until patients recovered from febrile neutropenia. If a patients had fever after 14 days, the chief physician decided if additional treatment should be administered.</p><p>The therapeutic effect was tested by G testing and GM testing twice a week until patients recovered from febrile neutropenia. Examination by chest CT was conducted weekly. The liver and renal function was examined weekly. Routine analysis for blood was tested once for every 2 days.</p><p>Voriconazole was used as the first-line treatment for patients in every 12 h via I.V. injection. The initiating injection dose of voriconazole was 400 mg, then the dose was decreased to 200 mg for subsequent injections. The chief physician decided if the treatment was ineffective or if an adverse effect occurred. The end-point for the antifungal treatment was patient recovery from febrile neutropenia or when a patient quit treatment due to any reason.</p></sec><sec><title>Outcomes and follow-up</title><p>The survival rate of patients who recovered from neutropenia by Day 14 was set as the primary end-point. Patients with severe neutropenic within a maximum of 60 days after receiving treatment or who demonstrated severe adverse events were excluded from data analysis. The ratio of diagnosed IFD patients and duration of persistent fever were used as the secondary end-points. The safety of the treatment was demonstrated as the rate of patients quitting treatment due to ineffectiveness or adverse events during the treatment. The indicators of cost-effectiveness were the ratio of patients who received antifungal therapy, duration and expenses of antifungal therapy, and patient hospitalization.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>The data analysis was conducted by use of SPSS (release 17.0, SPSS, Inc., Chicago, IL, USA). For categorical variables, data were compared using &#x003c7;<sup>2</sup> tests or Fisher&#x02019;s exact probability test. Measurement variables were tested by the 2 independent-samples Wilcoxon rank sum test. Subgroup analysis was used in the stratification of induction and consolidation chemotherapy.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="intro|subjects"><title>General information and characteristics of patients</title><p>There were 138 patients (86 males and 52 females) in the empirical group and 130 patients (75 males and 55 females) in the preemptive group. The median duration of neutropenia for all patients from both groups was 13 days, with no significant difference observed between groups. The median age for patients in the empirical group was 38 years (ranging from 18 to 77 years) and the median age for the preemptive group was 38 years (ranging from 18 to 81 years). <xref ref-type="table" rid="t1-medscimonit-22-4226">Table 1</xref> shows the cases of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed-lineage acute leukemia (MAL), and multiple myeloma (MM) among all patients. The phase of chemotherapy (induction, relapse and consolidation), application of antifungal prophylaxis for patients, intensity and duration of neutropenia, and duration of fever are documented in <xref ref-type="table" rid="t1-medscimonit-22-4226">Table 1</xref>.</p></sec><sec><title>Overall survival rate and causes of death</title><p>The overall survival rate for patients in the preemptive group was 94.6% compared with 97.1% in the empirical group (<italic>P</italic>=0.305), suggesting the survival rate was similar (<xref ref-type="table" rid="t2-medscimonit-22-4226">Table 2</xref>).</p><p>There were 11 deaths recorded, including 4 IFD patients (1 in the empirical group and 3 in the preemptive group), 4 patients with bacterial septicemia, 2 with unclear septicemia, and 1 with cardiogenic shock. The IFD-associated death rates were 0.7% and 2.3% for the empirical and preemptive group (<italic>P</italic>=0.573), receptively, but this difference was not significant (<xref ref-type="table" rid="t2-medscimonit-22-4226">Table 2</xref>).</p></sec><sec><title>Proven and probable IFD</title><p>IFD was observed in 12 (9.2%) patients in the preemptive group, which was significantly higher than the 3 (2.2%) cases in the empirical group (<xref ref-type="table" rid="t2-medscimonit-22-4226">Table 2</xref>). Moreover, out of these 12 IFD cases in the preemptive group, 8 were pulmonary aspergillosis (including 6 cases of baseline IFD and 2 cases of breakthrough IFD) and the rest were candidiasis (including 2 cases of baseline IFD and 2 cases of breakthrough IFD). Among these 4 cases of candidiasis, there were 2 cases of <italic>Candida albicans</italic>, 1 case of <italic>Candida tropicalis,</italic> and 1 case of <italic>Candida glabrata</italic>. For IFD cases in the empirical group, only 2 cases of baseline IFD and 1 case of breakthrough IFD were observed (<xref ref-type="table" rid="t2-medscimonit-22-4226">Table 2</xref>).</p></sec><sec><title>Application of antifungal therapy</title><p>According our data, application of antifungal therapy (26 cases, 20%, P&#x0003c;0.001) in the preemptive group was significantly lower than in the empirical group (43 cases, 31.2%) (<xref ref-type="table" rid="t3-medscimonit-22-4226">Table 3</xref>), which is consisted with previous observation [<xref rid="b11-medscimonit-22-4226" ref-type="bibr">11</xref>]. Among 26 cases in the preemptive group, 2 had persistent or recurrent fever; and the other 24 cases were clinical manifestations-positive or non-invasive diagnosis-positive, including 13 cases of pneumonia, 2 cases of severe mucositis, 3 cases of G test-positive, 3 cases of GM test-positive, 2 cases of sinusitis, and 1 case of diarrhea. In the empirical group, 25 cases had persistent or recurrent fever between day 4 and day 14 after antibacterial treatment initiation (<xref ref-type="table" rid="t3-medscimonit-22-4226">Table 3</xref>). The other cases were 13 cases of pneumonia, 2 cases of severely mucositis, 2 cases of G test-positive, and 1 case of GM test-positive (<xref ref-type="table" rid="t3-medscimonit-22-4226">Table 3</xref>).</p><p>The average time of antifungal therapy for the empirical and preemptive groups were 20.0&#x000b1;4.7 days and 13.8&#x000b1;4.7, respectively, which is statistically significant (<xref ref-type="table" rid="t3-medscimonit-22-4226">Table 3</xref>). The cost for each group was calculated and compared using the Chinese currency, Renminbi (RMB). The average expense of antifungal therapy for empirical and preemptive groups was RMB 12 104&#x000b1;3719 and RMB 8379&#x000b1;2253, respectively. Length of hospital stay was similar between the 2 groups of patients (<xref ref-type="table" rid="t3-medscimonit-22-4226">Table 3</xref>). Moreover, 6 patients in the empirical group and 5 patients in the preemptive group demonstrated inefficacious voriconazole treatment. Two patients in the empirical group and 1 patient in the preemptive group quit treatment due to adverse reactions to voriconazole.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Empirical antifungal therapy is a commonly used strategy to treat hematological disease for reducing mortality of IFD patients. However, the effectiveness of this strategy is still controversial due to lack of reliable data [<xref rid="b17-medscimonit-22-4226" ref-type="bibr">17</xref>,<xref rid="b18-medscimonit-22-4226" ref-type="bibr">18</xref>]. Generally, empirical antifungal therapy is initiated if persistent fever or recurrent fever is observed in patients and is terminated at disappearance of fever [<xref rid="b8-medscimonit-22-4226" ref-type="bibr">8</xref>,<xref rid="b19-medscimonit-22-4226" ref-type="bibr">19</xref>&#x02013;<xref rid="b22-medscimonit-22-4226" ref-type="bibr">22</xref>]. However, it is questionable to set the appearance and disappearance of fever as the initiation and termination point of antifungal therapy, since fever is not a specific symptom of IFD [<xref rid="b18-medscimonit-22-4226" ref-type="bibr">18</xref>,<xref rid="b23-medscimonit-22-4226" ref-type="bibr">23</xref>&#x02013;<xref rid="b25-medscimonit-22-4226" ref-type="bibr">25</xref>]. Moreover, application of empirical antifungal therapy may result certain disadvantages, such as over-treatment or higher expense. However, since more diagnostic technologies, such as G test, GM test, Chest CT, and polymerase chain reaction (PCR), are now used for early detection of IFD, it is possible to determine more precise initiating points for antifungal treatment [<xref rid="b9-medscimonit-22-4226" ref-type="bibr">9</xref>,<xref rid="b26-medscimonit-22-4226" ref-type="bibr">26</xref>,<xref rid="b27-medscimonit-22-4226" ref-type="bibr">27</xref>]. Therefore, diagnosis-based preemptive antifungal therapy has become an alternative strategy which allows patients receiving antifungal treatment as early as possible to achieve a better outcome and decrease overuse of antifungal drugs.</p><p>However, preemptive therapy is not recommended as standard care due to the insensitivity and un-specificity of diagnostic tools, and the initiating point of treatment is not yet well defined. Moreover, the delayed initiation of treatment may increase mortality. Segal et al. suggested that the initiation of antifungal therapy in febrile neutropenic patients could be determined by chest CT and experimental examinations [<xref rid="b25-medscimonit-22-4226" ref-type="bibr">25</xref>]. In our study, antifungal therapy was recommended only to those patients who had clinical manifestations, even with normal results of G testing, GM testing, and chest CT.</p><p>According to previously reports, analysis conducted by pooling the results of published randomized trials of empirical treatment with polyenes demonstrated the expected survival rate of empirical therapy was 1677 of 1846 (90.8%; 95% CI, 89.5&#x02013;92.2%) [<xref rid="b11-medscimonit-22-4226" ref-type="bibr">11</xref>,<xref rid="b15-medscimonit-22-4226" ref-type="bibr">15</xref>]. The same reports also suggested that a noninferiority margin of &#x02212;8% was chosen on the basis of guidelines issued by the Center for Drug Evaluation and Research and the Committee for Proprietary Medicinal Products [<xref rid="b11-medscimonit-22-4226" ref-type="bibr">11</xref>], and the use of a &#x02212;10% non-inferiority margin for evaluation of new antibacterials whose expected success rate is 90% [<xref rid="b16-medscimonit-22-4226" ref-type="bibr">16</xref>]. In the preemptive group of our study, only 26 (18.6%) of the intent-to-treat cases received antifungal therapy, and the overall survival rate was 94.6%, which is similar to previous reports of the survival rate in empirical therapy [<xref rid="b11-medscimonit-22-4226" ref-type="bibr">11</xref>,<xref rid="b15-medscimonit-22-4226" ref-type="bibr">15</xref>]. Therefore, application of preemptive therapy did not increase the mortality of the intent-to-treat group in a Chinese population, and is consistent with previous reports from Western countries [<xref rid="b11-medscimonit-22-4226" ref-type="bibr">11</xref>].</p><p>The survival rates of the preemptive and empirical groups were similar in our study, and we also noticed that the incidence of IFD cases was significantly higher (12 cases, 9.2%) in the preemptive group than in the empirical group (3 cases, 2.3%). A previous report evaluated the feasibility of preemptive therapy based on clinical symptoms, galactomannan antigenemia (cut-off for antigen level, 0.5 ng/mL), lung CT, and bronchoalveolar lavage [<xref rid="b9-medscimonit-22-4226" ref-type="bibr">9</xref>]. The data indicated that fewer patients meet criteria for preemptive treatment than empirical treatment, which is consistent with our observations. However, due to it open design, this report could not determine whether preemptive treatment was non-inferior to empirical treatment [<xref rid="b9-medscimonit-22-4226" ref-type="bibr">9</xref>]. In another trial, the incident rate of IFD cases was also higher in the preemptive group than in the empirical group (9.1% <italic>vs.</italic> 2.7%)4[<xref rid="b11-medscimonit-22-4226" ref-type="bibr">11</xref>]. Taken together, these findings may suggest that the low IFD incidence rate may reflect the lower positive predictive value of diagnostic investigations when the incidence of IFD is low [<xref rid="b11-medscimonit-22-4226" ref-type="bibr">11</xref>]. Therefore, the fact that more patients in the empirical group received antifungal treatment may have decreased the incidence rate of IFD but conferred little benefit to overall survival rate. We also noticed that the IFD-related deaths in the preemptive mainly occurred in elderly patients or patients whose performance score (PS) was higher than 2 (data not shown). This observation suggests that empirical therapy may be preferable for elderly or high PS patients to avoid IFD-related death, while preemptive treatment is recommended for younger or low PS patients. However, further investigation is needed to validate this speculation.</p><p>The average durations of antifungal therapy for empirical and preemptive groups were 20.0&#x000b1;4.7 days and 13.8&#x000b1;4.7 days, respectively. Moreover, the average expense for preemptive antifungal treatment was 8379.00&#x000b1;2253.00 CNY in this study. Although this result was not concluded by a completely randomized analysis, the duration and expense for antifungal therapy was significantly lower in the preemptive group. In China, due to the large population and relatively scarce hospitals, treatments with lower costs and shorter regimens are preferred. As a broad-spectrum antifungal agent, the therapeutic effect of voriconazole is comparable with amphotericin B liposome. We found voriconazole was well tolerated, and only 2 patients in the empirical group and 1 in the preemptive groups quit treatment.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Our data demonstrate that the preemptive antifungal therapy did not increase the IFD mortality compared to empirical therapy in patients with febrile neutropenic hematological malignancy, but preemptive antifungal therapy is an economically preferable medical practice in China. However, the increased incidence of IFD in the preemptive antifungal therapy group also suggest that the age and PS score of patients were factors for selecting the strategy. Moreover, to apply the preemptive strategy more accurately, clinical manifestations, physical signs, and more diagnostic methods (e.g., different imaging technics, biological markers, or PCR) have to be carefully assessed to achieve more effective preventive antifungal therapy.</p></sec></body><back><fn-group><fn id="fn8-medscimonit-22-4226"><p><bold>Source of support:</bold> Departmental sources</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-22-4226"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>TJ</given-names></name><name><surname>Anaissie</surname><given-names>EJ</given-names></name><name><surname>Denning</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America</article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><fpage>327</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">18177225</pub-id></element-citation></ref><ref id="b2-medscimonit-22-4226"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maertens</surname><given-names>J</given-names></name><name><surname>Marchetti</surname><given-names>O</given-names></name><name><surname>Herbrecht</surname><given-names>R</given-names></name><etal/></person-group><article-title>European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 &#x02013; 2009 update</article-title><source>Bone Marrow Transplant</source><year>2011</year><volume>46</volume><fpage>709</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">20661235</pub-id></element-citation></ref><ref id="b3-medscimonit-22-4226"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallejo</surname><given-names>C</given-names></name><name><surname>Barberan</surname><given-names>J</given-names></name></person-group><article-title>Empirical antifungal treatment: A valid alternative for invasive fungal infection</article-title><source>Rev Esp Quimioter</source><year>2011</year><volume>24</volume><fpage>117</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">21947092</pub-id></element-citation></ref><ref id="b4-medscimonit-22-4226"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagano</surname><given-names>L</given-names></name><name><surname>Caira</surname><given-names>M</given-names></name><name><surname>Candoni</surname><given-names>A</given-names></name><etal/></person-group><article-title>The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM &#x02013; 2004 study</article-title><source>Haematologica</source><year>2006</year><volume>91</volume><fpage>1068</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">16885047</pub-id></element-citation></ref><ref id="b5-medscimonit-22-4226"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortun</surname><given-names>J</given-names></name><name><surname>Carratala</surname><given-names>J</given-names></name><name><surname>Gavalda</surname><given-names>J</given-names></name><etal/></person-group><trans-title xml:lang="en">Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update</trans-title><source>Enferm Infecc Microbiol Clin</source><year>2011</year><volume>29</volume><fpage>435</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">21474210</pub-id></element-citation></ref><ref id="b6-medscimonit-22-4226"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikolajewska</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Ruhnke</surname><given-names>M</given-names></name></person-group><article-title>Antifungal treatment strategies in patients with haematological diseases or cancer: From prophylaxis to empirical, pre-emptive and targeted therapy</article-title><source>Mycoses</source><year>2012</year><volume>55</volume><fpage>2</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">21554421</pub-id></element-citation></ref><ref id="b7-medscimonit-22-4226"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freifeld</surname><given-names>AG</given-names></name><name><surname>Bow</surname><given-names>EJ</given-names></name><name><surname>Sepkowitz</surname><given-names>KA</given-names></name><etal/></person-group><collab>Infectious Diseases Society of Amreica</collab><article-title>Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America</article-title><source>Clin Infect Dis</source><year>2011</year><volume>52</volume><fpage>427</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">21205990</pub-id></element-citation></ref><ref id="b8-medscimonit-22-4226"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>SJ</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Slavin</surname><given-names>MA</given-names></name><name><surname>Kong</surname><given-names>DC</given-names></name></person-group><article-title>Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients</article-title><source>Expert Rev Pharmacoecon Outcomes Res</source><year>2013</year><volume>13</volume><fpage>227</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">23570433</pub-id></element-citation></ref><ref id="b9-medscimonit-22-4226"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maertens</surname><given-names>J</given-names></name><name><surname>Theunissen</surname><given-names>K</given-names></name><name><surname>Verhoef</surname><given-names>G</given-names></name><etal/></person-group><article-title>Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study</article-title><source>Clin Infect Dis</source><year>2005</year><volume>41</volume><fpage>1242</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">16206097</pub-id></element-citation></ref><ref id="b10-medscimonit-22-4226"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefani</surname><given-names>PM</given-names></name><name><surname>Gottardi</surname><given-names>M</given-names></name><name><surname>Zanetti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Preemptive antifungal therapy among neutropenic patients</article-title><source>Clin Infect Dis</source><year>2006</year><volume>42</volume><fpage>1507</fpage><lpage>8</lpage><comment>author reply 1508&#x02013;9</comment><pub-id pub-id-type="pmid">16619177</pub-id></element-citation></ref><ref id="b11-medscimonit-22-4226"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordonnier</surname><given-names>C</given-names></name><name><surname>Pautas</surname><given-names>C</given-names></name><name><surname>Maury</surname><given-names>S</given-names></name><etal/></person-group><article-title>Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><fpage>1042</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">19281327</pub-id></element-citation></ref><ref id="b12-medscimonit-22-4226"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hachem</surname><given-names>RY</given-names></name><name><surname>Kontoyiannis</surname><given-names>DP</given-names></name><name><surname>Chemaly</surname><given-names>RF</given-names></name><etal/></person-group><article-title>Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: Low sensitivity for <italic>Aspergillus fumigatus</italic> infection in hematologic malignancy patients</article-title><source>J Clin Microbiol</source><year>2009</year><volume>47</volume><fpage>129</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">19005145</pub-id></element-citation></ref><ref id="b13-medscimonit-22-4226"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgiadou</surname><given-names>SP</given-names></name><name><surname>Sipsas</surname><given-names>NV</given-names></name><name><surname>Marom</surname><given-names>EM</given-names></name><name><surname>Kontoyiannis</surname><given-names>DP</given-names></name></person-group><article-title>The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts</article-title><source>Clin Infect Dis</source><year>2011</year><volume>52</volume><fpage>1144</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">21467021</pub-id></element-citation></ref><ref id="b14-medscimonit-22-4226"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friendlander</surname><given-names>AH</given-names></name><name><surname>Ettinger</surname><given-names>RL</given-names></name></person-group><article-title>Karnofsky performance status scale</article-title><source>Spec Care Dentist</source><year>2009</year><volume>29</volume><fpage>147</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">19573040</pub-id></element-citation></ref><ref id="b15-medscimonit-22-4226"><label>15</label><element-citation publication-type="journal"><article-title>Empiric antifungal therapy in febrile granulocytopenic patients</article-title><collab>EORTC International Antimicrobial Therapy Cooperative Group</collab><source>Am J Med</source><year>1989</year><volume>86</volume><fpage>668</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">2658574</pub-id></element-citation></ref><ref id="b16-medscimonit-22-4226"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohmel</surname><given-names>J</given-names></name></person-group><article-title>Statistical considerations of FDA and CPMP rules for the investigation of new anti-bacterial products</article-title><source>Stat Med</source><year>2001</year><volume>20</volume><fpage>2561</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">11523069</pub-id></element-citation></ref><ref id="b17-medscimonit-22-4226"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castagnola</surname><given-names>E</given-names></name><name><surname>Mikulska</surname><given-names>M</given-names></name><name><surname>Barabino</surname><given-names>P</given-names></name><etal/></person-group><article-title>Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on</article-title><source>Expert Opin Emerg Drugs</source><year>2013</year><volume>18</volume><fpage>263</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">23777534</pub-id></element-citation></ref><ref id="b18-medscimonit-22-4226"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>JE</given-names></name><name><surname>Powers</surname><given-names>J</given-names></name><name><surname>Walsh</surname><given-names>T</given-names></name><etal/></person-group><article-title>Forum report: Issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients</article-title><source>Clin Infect Dis</source><year>2003</year><volume>36</volume><fpage>S117</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12679895</pub-id></element-citation></ref><ref id="b19-medscimonit-22-4226"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallejo Llamas</surname><given-names>JC</given-names></name><name><surname>Ruiz-Camps</surname><given-names>I</given-names></name></person-group><trans-title xml:lang="en">Invasive fungal infection in haematology patients</trans-title><source>Enferm Infecc Microbiol Clin</source><year>2012</year><volume>30</volume><fpage>572</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">23079614</pub-id></element-citation></ref><ref id="b20-medscimonit-22-4226"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>H</given-names></name><name><surname>Sawa</surname><given-names>M</given-names></name><name><surname>Yanada</surname><given-names>M</given-names></name><etal/></person-group><article-title>Micafungin for empirical antifungal therapy in patients with febrile neutropenia: Multicenter phase 2 study</article-title><source>Int J Hematol</source><year>2013</year><volume>98</volume><fpage>231</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">23857638</pub-id></element-citation></ref><ref id="b21-medscimonit-22-4226"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Cheong</surname><given-names>JW</given-names></name><name><surname>Min</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: A multicenter, prospective, open-label, observational study in Korea</article-title><source>J Korean Med Sci</source><year>2014</year><volume>29</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">24431907</pub-id></element-citation></ref><ref id="b22-medscimonit-22-4226"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>TJ</given-names></name><name><surname>Teppler</surname><given-names>H</given-names></name><name><surname>Donowitz</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>1391</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">15459300</pub-id></element-citation></ref><ref id="b23-medscimonit-22-4226"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Pauw</surname><given-names>B</given-names></name></person-group><article-title>Preventative use of antifungal drugs in patients treated for cancer</article-title><source>J Antimicrob Chemother</source><year>2004</year><volume>53</volume><fpage>130</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">14729743</pub-id></element-citation></ref><ref id="b24-medscimonit-22-4226"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Pauw</surname><given-names>BE</given-names></name></person-group><article-title>Between over- and undertreatment of invasive fungal disease</article-title><source>Clin Infect Dis</source><year>2005</year><volume>41</volume><fpage>1251</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16206098</pub-id></element-citation></ref><ref id="b25-medscimonit-22-4226"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal</surname><given-names>BH</given-names></name><name><surname>Almyroudis</surname><given-names>NG</given-names></name><name><surname>Battiwalla</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44</volume><fpage>402</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17205448</pub-id></element-citation></ref><ref id="b26-medscimonit-22-4226"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheat</surname><given-names>LJ</given-names></name><name><surname>Walsh</surname><given-names>TJ</given-names></name></person-group><article-title>Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2008</year><volume>27</volume><fpage>245</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">18193305</pub-id></element-citation></ref><ref id="b27-medscimonit-22-4226"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marr</surname><given-names>KA</given-names></name><name><surname>Balajee</surname><given-names>SA</given-names></name><name><surname>McLaughlin</surname><given-names>L</given-names></name><etal/></person-group><article-title>Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance</article-title><source>J Infect Dis</source><year>2004</year><volume>190</volume><fpage>641</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">15243943</pub-id></element-citation></ref><ref id="b28-medscimonit-22-4226"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athanasakis</surname><given-names>K</given-names></name><name><surname>Petrakis</surname><given-names>I</given-names></name><name><surname>Kyriopoulos</surname><given-names>J</given-names></name></person-group><article-title>Posaconazole <italic>vs</italic>. fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: A cost-effectiveness analysis in Greece</article-title><source>J Med Econ</source><year>2013</year><volume>16</volume><fpage>678</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">23448409</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-medscimonit-22-4226" position="float"><label>Table 1</label><caption><p>Patient characteristics in the per-protocol analysis.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Characteristics</th><th valign="bottom" align="center" rowspan="1" colspan="1">Empirical (n=138)</th><th valign="bottom" align="center" rowspan="1" colspan="1">Preemptive (n=130)</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Median age</td><td valign="middle" align="center" rowspan="1" colspan="1">38</td><td valign="middle" align="center" rowspan="1" colspan="1">38</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Age range</td><td valign="middle" align="center" rowspan="1" colspan="1">18&#x02013;77</td><td valign="middle" align="center" rowspan="1" colspan="1">18&#x02013;81</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Female sex (percentage)</td><td valign="middle" align="center" rowspan="1" colspan="1">52 (37.7%)</td><td valign="middle" align="center" rowspan="1" colspan="1">55 (42.3%)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Acute myeloid leukemia (AML)</td><td valign="middle" align="center" rowspan="1" colspan="1">95 (68.8%)</td><td valign="middle" align="center" rowspan="1" colspan="1">90 (69.2%)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Acute lymphoblastic leukemia (ALL)</td><td valign="middle" align="center" rowspan="1" colspan="1">35 (25.3%)</td><td valign="middle" align="center" rowspan="1" colspan="1">33 (25.4%)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Mixed-lineage acute leukemia (MAL)</td><td valign="middle" align="center" rowspan="1" colspan="1">6 (4.4%)</td><td valign="middle" align="center" rowspan="1" colspan="1">5 (3.8%)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Multiple myeloma(MM)</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (1.5%)</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (1.6%)</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1"><bold>Phase of chemotherapy</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Induction therapy</td><td valign="middle" align="center" rowspan="1" colspan="1">38 (27.5%)</td><td valign="middle" align="center" rowspan="1" colspan="1">33 (25.4%)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Relapse therapy</td><td valign="middle" align="center" rowspan="1" colspan="1">35 (25.4%)</td><td valign="middle" align="center" rowspan="1" colspan="1">34 (26.1%)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Consolidation therapy</td><td valign="middle" align="center" rowspan="1" colspan="1">65 (47.1%)</td><td valign="middle" align="center" rowspan="1" colspan="1">63 (48.5%)</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1"><bold>Antifungal prophylaxis</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Any</td><td valign="middle" align="center" rowspan="1" colspan="1">114 (82.6%)</td><td valign="middle" align="center" rowspan="1" colspan="1">108 (83.1%)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Fluconazole</td><td valign="middle" align="center" rowspan="1" colspan="1">15 (10.9%)</td><td valign="middle" align="center" rowspan="1" colspan="1">16 (12.6%)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Itraconazole</td><td valign="middle" align="center" rowspan="1" colspan="1">9 (6.5%)</td><td valign="middle" align="center" rowspan="1" colspan="1">6 (4.6%)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Neutropenia for &#x0003e;10 daysc</td><td valign="middle" align="center" rowspan="1" colspan="1">99 (71.7%)</td><td valign="middle" align="center" rowspan="1" colspan="1">94 (72.3%)</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1"><bold>Duration of neutrophil count &#x0003c;500 neutrophils/mm</bold><bold><sup>3</sup></bold><bold>, days</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Median (IQR)</td><td valign="middle" align="center" rowspan="1" colspan="1">13 (9&#x02013;19)</td><td valign="middle" align="center" rowspan="1" colspan="1">13 (9&#x02013;20)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Range</td><td valign="middle" align="center" rowspan="1" colspan="1">4&#x02013;56</td><td valign="middle" align="center" rowspan="1" colspan="1">4&#x02013;50</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Neutropenia before chemotherapy</td><td valign="middle" align="center" rowspan="1" colspan="1">20 (14.5%)</td><td valign="middle" align="center" rowspan="1" colspan="1">19 (14.6%)</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">Duration of neutropenia before chemotherapy,</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Median days (IQR)</td><td valign="middle" align="center" rowspan="1" colspan="1">4 (3&#x02013;7)</td><td valign="middle" align="center" rowspan="1" colspan="1">5 (4&#x02013;7)</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1"><bold>Duration of Fever(</bold>&#x02265;<bold>38.0&#x000b0;C)</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Days (IQR)</td><td valign="middle" align="center" rowspan="1" colspan="1">3 (2&#x02013;6)</td><td valign="middle" align="center" rowspan="1" colspan="1">4 (2&#x02013;5)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Range</td><td valign="middle" align="center" rowspan="1" colspan="1">1&#x02013;16</td><td valign="middle" align="center" rowspan="1" colspan="1">1&#x02013;16</td></tr></tbody></table></table-wrap><table-wrap id="t2-medscimonit-22-4226" position="float"><label>Table 2</label><caption><p>Efficacy and end points in the per-protocol analysis(n=268).</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">End point</th><th valign="middle" align="center" rowspan="1" colspan="1">Empirical (n=138)</th><th valign="middle" align="center" rowspan="1" colspan="1">Preemptive (n=130)</th><th valign="middle" align="center" rowspan="1" colspan="1">Difference (95%CI)</th><th valign="middle" align="center" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Survival rate</td><td valign="middle" align="right" rowspan="1" colspan="1">134 (97.1%)</td><td valign="middle" align="right" rowspan="1" colspan="1">123 (94.6%)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.5 (&#x02212;5.9 to 1.4)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.305</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Death cases</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (2.9%)</td><td valign="middle" align="right" rowspan="1" colspan="1">7 (5.4%)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IFD cases</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (2.2%)</td><td valign="middle" align="right" rowspan="1" colspan="1">12 (9.2%)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;7.0 (&#x02212;12.3 to &#x02212;1.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td colspan="5" valign="middle" align="left" rowspan="1"><bold>Baseline IFD</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Aspergillus</td><td valign="middle" align="right" rowspan="1" colspan="1">2 ()</td><td valign="middle" align="right" rowspan="1" colspan="1">6 ()</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Candida</td><td valign="middle" align="right" rowspan="1" colspan="1">0 ()</td><td valign="middle" align="right" rowspan="1" colspan="1">2 ()</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="5" valign="middle" align="left" rowspan="1"><bold>Breakthrough IFD</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Aspergillus</td><td valign="middle" align="right" rowspan="1" colspan="1">1 ()</td><td valign="middle" align="right" rowspan="1" colspan="1">2 ()</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Candida</td><td valign="middle" align="right" rowspan="1" colspan="1">0 ()</td><td valign="middle" align="right" rowspan="1" colspan="1">2 ()</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IFD related mortality</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (0.7%)</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (2.3%)</td><td valign="middle" align="center" rowspan="1" colspan="1">1.6 (&#x02212;1.9 to 1.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.573</td></tr></tbody></table></table-wrap><table-wrap id="t3-medscimonit-22-4226" position="float"><label>Table 3</label><caption><p>Antifungal therapy in the per-protocol analysis (n=268).</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">End point</th><th valign="middle" align="center" rowspan="1" colspan="1">Empirical (Intent to treat: n=138)</th><th valign="middle" align="center" rowspan="1" colspan="1">Preemptive (Intent to treat: n=130)</th><th valign="middle" align="center" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Antifungal treated cases</td><td valign="middle" align="center" rowspan="1" colspan="1">43 (31.2%)</td><td valign="middle" align="center" rowspan="1" colspan="1">26 (20.0%)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="4" valign="middle" align="left" rowspan="1"><bold>Reason for antifungal treatment</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Isolated fever between day 4 and day 14 after antibacterial treatment initiation</td><td valign="middle" align="center" rowspan="1" colspan="1">25 (58.1%)</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (7.7%)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Pneumonia</td><td valign="middle" align="center" rowspan="1" colspan="1">13 (30.2%)</td><td valign="middle" align="center" rowspan="1" colspan="1">13 (50.0%)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Severe mucositis</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (4.7%)</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (7.7%)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;G test positive</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (4.7%)</td><td valign="middle" align="center" rowspan="1" colspan="1">3 (11.5%)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;GM test positive</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (2.3%)</td><td valign="middle" align="center" rowspan="1" colspan="1">3 (11.5%)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Sinusitis or periorbital inflammation</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0%)</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (7.7%)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Diarrhea</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0%)</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (3.9%)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="4" valign="middle" align="left" rowspan="1"><bold>Duration of fever before antifungal treatment</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Median days (IQR)</td><td valign="middle" align="center" rowspan="1" colspan="1">4 (2&#x02013;5)</td><td valign="middle" align="center" rowspan="1" colspan="1">5 (4&#x02013;7)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td colspan="4" valign="middle" align="left" rowspan="1"><bold>Duration of fever after antifungal treatment</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Median days (IQR)</td><td valign="middle" align="center" rowspan="1" colspan="1">3 (2&#x02013;5)</td><td valign="middle" align="center" rowspan="1" colspan="1">3 (2&#x02013;5)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.802</td></tr><tr><td colspan="4" valign="middle" align="left" rowspan="1"><bold>Duration of antifungal treatment</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Mean days &#x000b1;SD</td><td valign="middle" align="center" rowspan="1" colspan="1">20.0&#x000b1;4.7</td><td valign="middle" align="center" rowspan="1" colspan="1">13.8&#x000b1;4.7</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="4" valign="middle" align="left" rowspan="1"><bold>Cost of antifungal(RMB)</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Mean &#x000b1;SD</td><td valign="middle" align="center" rowspan="1" colspan="1">12104&#x000b1;3719</td><td valign="middle" align="center" rowspan="1" colspan="1">8379&#x000b1;2253</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Range</td><td valign="middle" align="center" rowspan="1" colspan="1">5776&#x02013;25600</td><td valign="middle" align="center" rowspan="1" colspan="1">4560&#x02013;14896</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="4" valign="middle" align="left" rowspan="1"><bold>Length of hospitalization</bold></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Mean days &#x000b1;SD</td><td valign="middle" align="center" rowspan="1" colspan="1">34.0&#x000b1;11.3</td><td valign="middle" align="center" rowspan="1" colspan="1">32.7&#x000b1;9.3</td><td valign="middle" align="center" rowspan="1" colspan="1">0.283</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Range</td><td valign="middle" align="center" rowspan="1" colspan="1">17&#x02013;72</td><td valign="middle" align="center" rowspan="1" colspan="1">16&#x02013;71</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Treatment failure</td><td valign="middle" align="center" rowspan="1" colspan="1">6 (14.0%)</td><td valign="middle" align="center" rowspan="1" colspan="1">5 (19.2%)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.810</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Side effect</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (4.7%)</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (3.8%)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.874</td></tr></tbody></table></table-wrap></floats-group></article>